2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-162663
    VU0448088 1417616-42-2 98.67%
    VU0448088 (ML253) is a potent and cross the blood-brain barrier tricyclic muscarinic acetylcholine receptor subtype 4 (M4) positive allosteric modulator with EC50 values of 56, 176 nM for human and rat, respectively. VU0448088 has the potential for the research of psychotic.
    VU0448088
  • HY-163739
    LETC 951131-13-8 98.30%
    LETC is an orally active α-synuclein (α-Syn) aggregation inhibitor with an EC50 of 66 nM in transfected DH60.21 neuroblastoma cells. LETC can cross the blood-brain barrier. LETC can be used for the study of synucleinopathies.
    LETC
  • HY-164130
    AChE-IN-65 98704-22-4 98%
    AChE-IN-65 (Compound DABA_1) is a mixed inhibitor for acetylcholinesterase (AChE), with a Ki of 556.4 μM for Electrophorus electricus AChE.
    AChE-IN-65
  • HY-164703
    Lumateperone metabolite 1 1469777-40-9 98.26%
    Lumateperone metabolite 1 (Formula T) is a metabolite of Lumateperone (HY-17637). Lumateperone (ITI-007) is an orally active 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator
    Lumateperone metabolite 1
  • HY-164795
    SBI-810 1849603-79-7 98.25%
    SBI-810 is a blood-brain barrier-permeable NTSR1 modulator. SBI-810 promotes the recruitment of β-arrestin-2 to NTSR1 and antagonizes NTSR1-mediated Gq activation. SBI-810 inhibits excitatory synaptic transmission, NMDA receptor and extracellular signal-regulated kinase (ERK) signaling in spinal nociceptive neurons, reduces surface expression of Nav1.7 and action potential firing in primary sensory neurons, and attenuates C-fiber responses. SBI-810 effectively alleviates acute and chronic pain in various rodent models through peripheral and central modulation. SBI-810 is applicable to research related to multiple pain disorders.
    SBI-810
  • HY-164853
    Kanglexin 2228847-12-7 99.65%
    Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis.
    Kanglexin
  • HY-165677
    C22 Galactosylceramide 74645-25-3 99.9%
    C22 Galactosylceramide is a sphingolipid present in the central nervous system, exhibiting elevated levels in the spinal cord of mice on a methionine-restricted diet, while not affecting the brain or liver; furthermore, it has been identified in the postmortem hippocampus of Alzheimer's disease patients.
    C22 Galactosylceramide
  • HY-169004
    CBT-295 1623794-90-0 99.34%
    CBT-295 is an orally active autotaxin (ATX) inhibitor. CBT-295 exhibits a significant reduction in inflammatory cytokines like TGF-β, TNF-α and IL-6 levels, also reduced bile duct proliferation marker CK-19 and lowered liver fibrosis. The reversal of liver fibrosis with CBT-295 led to a reduction in blood and brain ammonia levels. CBT-295 also reduced neuroinflammation induced by ammonia. CBT-295 is promising for research of liver cirrhosis and associated encephalopathy.
    CBT-295
  • HY-169460
    6-Methoxy DMT 2426-88-2 98.2%
    6-Methoxy DMT (6-MeO-DMT) is derivative of N,N-dimethyltryptamine (HY-110062) that is a non-hallucinogenic compound.
    6-Methoxy DMT
  • HY-169675
    Lacripep 2243095-21-6
    Lacripep is a synthetic tear protein. Lacripep binds to and activates syndecan-1 (SDC1). Lacripep restores progenitor cell identity and epithelial barrier function. Lacripep resolves dry eye.
    Lacripep
  • HY-17038S
    Agomelatine-d6 1079389-42-6 99.05%
    Agomelatine-d6 is deuterium labeled Agomelatine. Agomelatine is a specific agonist of MT1 and MT2 receptors .
    Agomelatine-d6
  • HY-171177
    P5SA-2 864717-20-4 99.51%
    P5SA-2 is a selective allosteric activator of PPP5C. P5SA-2 exerts its effects by modulating the phosphatase domain of PPP5C and can increase PPP5C activity by 3.2-fold at 100 μM with an apparent affinity constant of 7.8 μM. P5SA-2 can be used in cancer and Alzheimer's disease research.
    P5SA-2
  • HY-172706
    DSPE-PEG5000-RVG29
    DSPE-PEG5000-RVG29 is a PEG compound which composed of DSPE and a Rabies virus glycoprotein 29 (RVG29). RVG29 can bind specifically to the nicotinic acetylcholine receptor (nAChR) at the blood-brain barrier (BBB) and cross over the BBB.
    DSPE-PEG5000-RVG29
  • HY-172967
    SARM1-IN-5 2762081-30-9 99.93%
    SARM1-IN-5 (compound 1-23-a) is a SARM1 inhibitor. SARM1-IN-5 can be used in the study of axonal degeneration related diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS).
    SARM1-IN-5
  • HY-172973
    TAU-IN-4 2109305-45-3 99.95%
    TAU-IN-4 (compound I1.21) is a potent Tau aggregation inhibitor with a KD of 1.58 μM. TAU-IN-4 can be used in the study of Alzheimer’s disease.
    TAU-IN-4
  • HY-172997
    GluN1/3A-IN-1 1147526-22-4 98.99%
    GluN1/3A-IN-1 (Compound GM-10) is a GluN1/GluN3A NMDA receptor inhibitor. GluN1/3A-IN-1 exhibits potent inhibitory activity against GluN1/GluN3A (IC50: 0.98 µM). GluN1/3A-IN-1 exerts its inhibitory effect by targeting the pre-M1 region and forming hydrogen bond interactions with key residues. GluN1/3A-IN-1 can be used to study GluN1/GluN3A-related neurological diseases.
    GluN1/3A-IN-1
  • HY-173276
    SARM1-IN-4 3069378-18-0 98%
    SARM1-IN-4 (Compound 7) is an orally active SARM1 inhibitor. After being orally administered at a dose of 50 mg/kg in a mouse model, it can reduce the level of plasma neurofilament light chain (NfL). SARM1-IN-4 prevents programmed axonal degeneration by inhibiting the NAD+ hydrolase activity of SARM1, and it can be used in research related to neurodegenerative diseases and neurological disorders (such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, and peripheral neuropathies, etc.).
    SARM1-IN-4
  • HY-173291
    Tau ligand-1 3063166-64-0 99.47%
    Tau ligand-1 (Compound 75) is a ligand for aggregated tau protein that can penetrate the blood-brain barrier. In tissues from patients with Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, and Pick's disease, Tau ligand-1 exhibits high affinity for aggregated tau protein, with equilibrium dissociation constant (KD) values ranging from 1 to 3.8 nM. Tau ligand-1 can serve as a potential positron emission tomography (PET) tracer and holds promise for application in positron emission tomography imaging studies of tau-related diseases in the central nervous system.
    Tau ligand-1
  • HY-173537
    D-myo-Inositol-1,2,4,5-tetraphosphate tetrasodium salt 154278-46-3 98%
    D-myo-Inositol-1,2,4,5-tetraphosphate (DL-Ins-(1,2,4,5)P4) tetrasodium is raracemic regioisomer of myo-inositol tetrakisphosphates (IP4s). D-myo-Inositol-1,2,4,5-tetraphosphate tetrasodium is an Ins(1,4,5)P3 receptor agonist with a Ki of 11 nM. D-myo-Inositol-1,2,4,5-tetraphosphate tetrasodium induces Ca2+ mobilization with an EC50 value of 0.22 μM in CHO cells.
    D-myo-Inositol-1,2,4,5-tetraphosphate tetrasodium salt
  • HY-17357S
    Nepafenac-d5 1246814-53-8 98.84%
    Nepafenac-d5 (AHR-9434-d5; AL-6515-d5) is the deuterium labeled Nepafenac (HY-17357). Nepafenac, a nonsteroidal anti-inflammatory agent, is a topically administered COX-2 inhibitor with an IC50 of 0.12 μM. Nepafenac exhibits only weak COX-1 inhibitory activity (IC50 = 64.3 μM). Nepafenac possesses unique prodrug properties, which enable it to rapidly convert into the active metabolite Amfenac (HY-17479) in the ocular tissues, thereby achieving high concentrations in the retina and choroid. Nepafenac reduces inflammation and pain by inhibiting the activity of cyclooxygenase (COX) enzymes and thereby decreasing the production of prostaglandin PGE₂. Nepafenac can delay the metastasis of uveal melanoma (UM) in rabbit eyes. Nepafenac is mainly used for pain management and inflammation control after ophthalmic surgeries.
    Nepafenac-d5
Cat. No. Product Name / Synonyms Application Reactivity